Read
- Fugitive Snowden granted a year's asylum in Russia, leaves airport
|
- Tsvangirai denounces Zimbabwe vote as 'huge farce'
|
- Polish priest's dismissal exposes rift over dialogue with Jews
- Fugitive Snowden leaves Moscow airport: representative
- Japan buys almost 90,000 tonnes U.S. western white via tender
Sponsored Links
AstraZeneca drug sales fall on patent expiries in second quarter
LONDON |
LONDON Aug 1 (Reuters) - AstraZeneca sales fell by a slightly more -than-expected 6 percent in the second quarter, hurt by loss of patent protection on key drugs, while earnings tumbled nearly a quarter due to a higher tax rate.
New Chief Executive Pascal Soriot is striving to turn around the business after a series of setbacks in research and a wave of patent expiries, but has warned that fixing Britain's second biggest drugmaker will take several years.
The group reiterated its expectation for a mid-to-high single digit percentage fall in revenue this year, while operating costs are now seen increasing by a low-to-mid single digit rate. Earnings are expected to decline significantly more than revenue in 2013.
Sales in the quarter were $6.232 billion, generating "core" earnings, which exclude certain items, down 23 percent at $1.20 a share, AstraZeneca said on Thursday.
Analysts had, on average, forecast sales of $6.248 billion and earnings of $1.20, according to Thomson Reuters I/B/E/S.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints


Follow Reuters